Amphastar Q4 revenue $135M (+11.7% YoY); GAAP EPS $0.66; full-year revenue $499M (+14.0% YoY)

Amphastar Pharmaceuticals, Inc.

2022-FY EPS reported $1.74 revenue$498,987,000

Q4 2022 net revenue $135.0M vs $120.9M YoY; GAAP net income $33.9M ($0.66 diluted EPS) vs $19.8M ($0.39).
Full-year 2022 net revenue $499.0M vs $437.8M, GAAP net income $91.4M ($1.74) vs $62.1M ($1.25).
Adjusted non-GAAP Q4 EPS $0.73, full-year $1.97; growth driven by epinephrine, Primatene MIST, and glucagon.
CEO cites strongest quarter and anticipates multiple new product launches in 2023.
No forward guidance provided; financial comparisons are to prior-year periods.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amphastar Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2022 results: revenue $499.0 million, net income $91.4 million, EPS $1.74 per share.

Period: the fiscal year ended December 31, 2022
Revenue: $499.0 million
Net income: $91.4 million
EPS: $1.74 per share
Result: reported results

Exact text from the filing

Net revenues of $499.0 million for the fiscal year ● GAAP net income of $91.4 million, or $1.74 per share, for the fiscal year ● Adjusted non-GAAP net income of $103.2 million, or $1.97 per share, for the fiscal year

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amphastar Pharmaceuticals, Inc. reported the three months ended December 31, 2022 results: revenue $135.0 million, net income $33.9 million, EPS $0.66 per share.

Period: the three months ended December 31, 2022
Revenue: $135.0 million
Net income: $33.9 million
EPS: $0.66 per share
Result: reported results

Exact text from the filing

Net revenues of $135.0 million for the fourth quarter ● GAAP net income of $33.9 million, or $0.66 per share, for the fourth quarter ● Adjusted non-GAAP net income of $37.6 million, or $0.73 per share, for the fourth quarter

View on SEC.gov

Browse all earnings releases →

Amphastar Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001297184-23-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.